Paper189368
Cancer chemotherapy: its role in the treatment strategy of hematologic malignancies and solid tumors.
Clarysse A and 2 others. Recent Results Cancer Res, 1976. Cited by 11 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Cancer chemotherapy: its role in the treatment strategy of hematologic malignancies and solid tumors. Papers, record 189368. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/189368
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Cancer chemotherapy: its role in the treatment strategy of hematologic malignancies and solid tumors.
- PubMed
Topics33
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cell Survival | Major topic |
| Neoplasms | Major topic |
| Adult | |
| Antimetabolites | |
| Brain Neoplasms | |
| Breast Neoplasms | |
| Cell Division | |
| Cell Physiological Phenomena | |
| Cell Transformation, Neoplastic | |
| Child | |
| Endocrine System Diseases | |
| Female | |
| Gastrointestinal Neoplasms | |
| Genital Neoplasms, Female | |
| Head and Neck Neoplasms | |
| Hodgkin Disease | |
| Hormones | |
| Humans | |
| Kidney Neoplasms | |
| Lung Neoplasms | |
| Lymphoma | |
| Male | |
| Melanoma | |
| Multiple Myeloma | |
| Neoplasms, Germ Cell and Embryonal | |
| Neoplasms, Nerve Tissue | |
| Polycythemia Vera | |
| Prostatic Neoplasms | |
| Sarcoma | |
| Skin Neoplasms | |
| Testicular Neoplasms | |
| Urinary Bladder Neoplasms |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 3,117,399 | Sequential instillation therapy with mitomycin C and adriamycin for superficial bladder tumors. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3117399 | PubMed |
| 750,105 | Chemotherapy, a double agent in respect of immune functions. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/750105 | PubMed |
| 535,129 | The multiplication of analogs, the best strategy for rapid extension of the oncostatic arsenal. How can they be compared experimentally? | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/535129 | PubMed |
| 373,923 | Preliminary results of a phase II trial of aclacinomycin in acute leukaemia and lymphosarcoma. An oncostatic anthracyclin that is rarely cardiotoxic and induces no alopecia. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/373923 | PubMed |
| 373,920 | Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation. | Cancer Chemother Pharmacol | 1978 | https://conductscience.org/library/papers/373920 | PubMed |
| 287,569 | Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/287569 | PubMed |
| 161,207 | Comparative pharmacology of three new nitrosourea analogues: RFCNU, RPCNU, and chlorozotocin. I. Oncostatic effects in mice. | Cancer Chemother Pharmacol | 1979 | https://conductscience.org/library/papers/161207 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/189368
GET https://conductscience.org/api/papers/v1/189368/authors